Détails du produit
Features and Advantages
- Native Conformation: Native sequences, tag-free and natural function.
- Reliable Activity: Biological activity calibrated against WHO/NIBSC standards.
- Stringent Quality Control: Protein content, purity, and cell-based bioactivity testing for each batch.
- Lowest Endotoxin level (<0.01 EU/ug).
- Safety Assurance: Sterile filtration through 0.2 μm membrane.
- AOF: Animal origin-free raw materials throughout the production process.
Synonyms
RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF
Source
Human VEGF165 Protein, Research Grade (VE5-H4213) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Quality Description
ACRO's Research-grade products are suitable for a wide range of cell culture applications, particularly for research use in academic institutions. These products are sterilized by filtration, followed by lyophilization where applicable. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. Biological activity is calibrated against WHO/NIBSC standards when available.
ACRO's Premium-grade (Pre-GMP) products are characterized by their high quality and enhanced safety profiles, making them ideal for early-stage discovery and manufacturing processes in cell therapy companies. A key advantage is their seamless transition to corresponding GMP-grade versions. Biological activity is calibrated against WHO/NIBSC standards when available. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. In addition, rigorous testing is conducted to ensure the absence of mycoplasma, HCD, and HCP, thereby guaranteeing product safety.
Les clients ont également consulté
Affichage des données
SDS-PAGE

Human VEGF165 Protein, Research Grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Human VEGF165 Protein, Research Grade (Cat. No. VE5-H4213) is more than 95% and the molecular weight of this protein is around 42-60 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA

Immobilized Human VEGF165 Protein, Research Grade (Cat. No. VE5-H4213) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 4-125 ng/mL (QC tested).
Protocol
Bioactivity-CELL BASE

Human VEGF165 Protein, Research Grade (Cat. No. VE5-H4213) stimulates Human VEGF R2 (Luc) HEK293 Reporter Cell. The specific activity of Human VEGF165 Protein, Research Grade is > 8.00 x 10^5 IU/mg, which is calibrated against human vascular endothelial growth factor 165 WHO International Standard (NIBSC code: 02/286) (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Vascular endothelial growth factor A
- Catégorie:
- Nombre de médicaments répertoriés:
54 Détails
- Nombre de médicaments cliniques:
61 Détails
- Étape de développement la plus élevée:
Approved



















